Reta 20mg (2 vials)

Product Name: Retatrutide
Form: Lyophilized powder (for reconstitution)
Molecular Class: Triple agonist (GLP-1, GIP, and glucagon receptor agonist)
Molecular Weight: ~4.2 kDa (peptide-based)

Description:
Retatrutide is an investigational research peptide designed to act as a potent triple agonist of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. By targeting all three incretin pathways, Retatrutide is being studied for its potential in regulating glucose metabolism, appetite suppression, energy expenditure, and body weight management.

Early-phase research has demonstrated significant reductions in body fat and improvements in metabolic parameters compared to single-pathway incretin mimetics. Its unique multi-pathway approach positions Retatrutide as a next-generation candidate in metabolic research.

Research Applications

• Investigation of multi-receptor agonism in obesity and type 2 diabetes models

• Exploration of energy balance and appetite suppression mechanisms

• Study of glucose homeostasis and insulin regulation

• Comparative research versus GLP-1 and dual agonists (e.g., Tirzepatide)

Disclaimer

• For Research Use Only – Not for human consumption, clinical use, or diagnostic purposes.

• This compound is not approved by Health Canada, the FDA, or any regulatory authority for medical use.

• Retatrutide is intended exclusively for laboratory research by qualified professionals.

• The supplier makes no claims regarding safety, efficacy, or approved applications in humans or animals.

• Handling should be performed with appropriate laboratory protective equipment under controlled conditions.